X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs VENUS REMEDIES - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD VENUS REMEDIES ALEMBIC LTD/
VENUS REMEDIES
 
P/E (TTM) x 54.8 -1.1 - View Chart
P/BV x 2.2 0.1 2,786.5% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 ALEMBIC LTD   VENUS REMEDIES
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
VENUS REMEDIES
Mar-18
ALEMBIC LTD/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs72126 57.2%   
Low Rs3461 55.5%   
Sales per share (Unadj.) Rs4.7301.8 1.6%  
Earnings per share (Unadj.) Rs6.1-24.9 -24.5%  
Cash flow per share (Unadj.) Rs6.22.5 245.4%  
Dividends per share (Unadj.) Rs0.200-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs40.7293.3 13.9%  
Shares outstanding (eoy) m267.0312.34 2,163.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.30.3 3,635.9%   
Avg P/E ratio x8.7-3.8 -230.8%  
P/CF ratio (eoy) x8.536.7 23.1%  
Price / Book Value ratio x1.30.3 408.5%  
Dividend payout %3.30-   
Avg Mkt Cap Rs m14,1391,154 1,225.5%   
No. of employees `000NA0.9 0.0%   
Total wages/salary Rs m207393 52.8%   
Avg. sales/employee Rs ThNM4,026.1-  
Avg. wages/employee Rs ThNM425.0-  
Avg. net profit/employee Rs ThNM-331.8-  
INCOME DATA
Net Sales Rs m1,2553,724 33.7%  
Other income Rs m37023 1,645.3%   
Total revenues Rs m1,6253,747 43.4%   
Gross profit Rs m111395 28.1%  
Depreciation Rs m38338 11.2%   
Interest Rs m2354 0.5%   
Profit before tax Rs m442-275 -160.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2432 75.8%   
Profit after tax Rs m1,630-307 -531.1%  
Gross profit margin %8.910.6 83.5%  
Effective tax rate %5.4-11.5 -47.2%   
Net profit margin %129.8-8.2 -1,575.6%  
BALANCE SHEET DATA
Current assets Rs m1,8672,638 70.8%   
Current liabilities Rs m5912,305 25.7%   
Net working cap to sales %101.68.9 1,136.7%  
Current ratio x3.21.1 275.9%  
Inventory Days Days94135 69.6%  
Debtors Days Days7446 158.7%  
Net fixed assets Rs m1,7914,871 36.8%   
Share capital Rs m534123 432.8%   
"Free" reserves Rs m10,3243,496 295.3%   
Net worth Rs m10,8583,619 300.0%   
Long term debt Rs m411,374 3.0%   
Total assets Rs m11,5917,509 154.4%  
Interest coverage x260.90.2 117,000.8%   
Debt to equity ratio x00.4 1.0%  
Sales to assets ratio x0.10.5 21.8%   
Return on assets %14.10.6 2,229.8%  
Return on equity %15.0-8.5 -177.0%  
Return on capital %15.21.6 960.1%  
Exports to sales %1.50-   
Imports to sales %21.013.9 151.3%   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263517 51.0%   
Fx inflow Rs m190-   
Fx outflow Rs m264517 51.1%   
Net fx Rs m-244-517 47.3%   
CASH FLOW
From Operations Rs m236514 45.8%  
From Investments Rs m-224-123 182.0%  
From Financial Activity Rs m-27-387 6.9%  
Net Cashflow Rs m-154 -352.4%  

Share Holding

Indian Promoters % 64.0 32.9 194.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 0.2 111.1%  
FIIs % 9.7 0.6 1,672.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 66.4 39.3%  
Shareholders   54,701 20,121 271.9%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   DISHMAN PHARMA  ELDER PHARMA  SUVEN LIFESCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare ALEMBIC LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat; Auto and Realty Stocks Witness Buying(Closing)

Indian share markets continued to witness volatility during closing hours and ended their day on a flat note. Gains were seen in the auto sector and realty sector.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

ALEMBIC LTD Announces Quarterly Results (3QFY19); Net Profit Down 41.9% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, ALEMBIC LTD has posted a net profit of Rs 32 m (down 41.9% YoY). Sales on the other hand came in at Rs 243 m (down 18.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

More Views on News

Most Popular

Why Super Investor Kenneth Andrade is Bullish on Agri Stocks...and So Are We(The 5 Minute Wrapup)

Jun 21, 2019

Andrade gives his take on agriculture, an industry from which we have already recommended two stocks.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

This Little-Known Opportunity Promises Both Health and Wealth for Your Grandchildren(Profit Hunter)

Jun 20, 2019

The next big opportunity that has the potential to make you both rich and healthy.

One Stock that Will Gain from the Electric Vehicle Disruption(The 5 Minute Wrapup)

Jun 25, 2019

Even if the share of the unorganized segment does not fall sharply, one player in the duopolistic battery sector has a lot to gain.

My Upcoming Stock Recommendation, Backed by Aberdeen Standard Investments, Scores 9.1/10(The 5 Minute Wrapup)

Jun 19, 2019

This month's Smart Money Secrets recommendation is from global super investor - Aberdeen Standard Investments.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Jun 27, 2019 03:29 PM

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD - TORRENT PHARMA COMPARISON

COMPARE ALEMBIC LTD WITH

MARKET STATS